[Drug sensitivity test against malignant gliomas]

Area of Science:

• Oncology
• Pharmacology
• Experimental Medicine

Context:

• Malignant brain tumors, particularly gliomas, present significant therapeutic challenges due to tumor heterogeneity.
• Accurate preclinical models are crucial for evaluating anticancer drug sensitivity and predicting clinical outcomes.
• Existing models vary in their ability to mimic human tumor biology and predict drug response.

Purpose:

• To evaluate and compare the utility of three distinct in vivo models for assessing anticancer drug sensitivity in malignant brain tumors.
• To determine the predictive value of each model for direct anticancer drug effects, biological response modifiers, and patient-derived gliomas.
• To identify the most suitable preclinical models for guiding chemotherapy selection in brain tumor treatment.

Summary:

• Three in vivo models were assessed: human glioma-bearing nude mice, methylcholantrene-induced mouse glioma models, and human gliomas in chick embryo chorioallantoic membranes (CAM).
• Human glioma-bearing nude mice demonstrated high utility for predicting direct anticancer drug effects, with ACNU and interferons tested.
• The chick embryo CAM model showed high grafting success and results comparable to nude mice, proving useful for predicting drug effects on patient-derived gliomas.

Impact:

• Human glioma-bearing nude mice are identified as highly predictive for direct anticancer drug effects.
• Immunocompetent mouse models offer insights into biological response modifiers and immunological changes.
• The chick embryo CAM model provides a viable, high-success-rate platform for drug sensitivity testing, especially for patient-derived gliomas.